Cyramza and Icterus - a phase IV clinical study of FDA data

Summary:

Icterus is reported as a side effect among people who take Cyramza (ramucirumab), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Keytruda, and have Gastric cancer.

The phase IV clinical study analyzes which people have Icterus when taking Cyramza. It is created by eHealthMe based on reports of 4,051 people who have side effects when taking Cyramza from the FDA, and is updated regularly.

What is Cyramza?

Cyramza has active ingredients of ramucirumab. eHealthMe is studying from 4,052 Cyramza users. Check the latest studies of Cyramza.

What is Icterus?

Icterus (yellowish pigmentation of the skin) is found to be associated with 1,921 drugs and 3,032 conditions by eHealthMe. Check the latest studies of Icterus.

On Jul, 10, 2026

4,051 people reported to have side effects when taking Cyramza.
Among them, 16 people (0.39%) have Icterus.

Among these 16 people:

How long have people been on Cyramza when they have Icterus? *

What is the gender of people who have Icterus when taking Cyramza? *

female: 46.15 %
male: 53.85 %

What is the age of people who have Icterus when taking Cyramza? *

What are other drugs people take besides Cyramza? *

Keytruda: 2 people, 12.50%
Tarceva: 1 person, 6.25%
Erlotinib Hydrochloride: 1 person, 6.25%
Amlodipine: 1 person, 6.25%

What are other side effects people have besides Icterus? *

Malignant Neoplasm Progression (cancer tumour came back): 3 people, 18.75%
Hepatic Failure (liver failure): 3 people, 18.75%
Abdominal Pain: 2 people, 12.50%
Pancreatic Cyst: 2 people, 12.50%
Anaemia (lack of blood): 2 people, 12.50%
Ascites (accumulation of fluid in the abdominal cavity): 2 people, 12.50%
Faeces Pale: 1 person, 6.25%
Alpha 1 Foetoprotein Abnormal: 1 person, 6.25%
Altered State Of Consciousness (altered state of mind): 1 person, 6.25%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 1 person, 6.25%

What are the existing conditions these people have? *

Metastatic Neoplasm (spreadable cancer tumour): 2 people, 12.50%
High Blood Pressure: 2 people, 12.50%
Hepatocellular Carcinoma (liver cancer): 2 people, 12.50%
Gastric Cancer (stomach cancer): 2 people, 12.50%
Rectal Cancer (cancer of rectum): 1 person, 6.25%
Metastatic Gastric Cancer (cancer types can spread to the stomach from other place): 1 person, 6.25%
Lung Neoplasm Malignant (cancer tumour of lung): 1 person, 6.25%
Lung Cancer - Non-Small Cell (lung cancer): 1 person, 6.25%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 6.25%
Gastrointestinal Carcinoma (cancer of stomach or intestine): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Cyramza and have Icterus?

- Check whether Icterus is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cyramza:

Cyramza (4,052 reports)

Icterus treatments and more:

Icterus (33,621 reports)

Browse all side effects of Cyramza:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Icterus:

Icterus (1,921 drugs)

Browse all the conditions that are associated with Icterus:

Icterus (3,032 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ramucirumab (the active ingredients of Cyramza) and Cyramza (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.